{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:18:51Z","timestamp":1789723131512,"version":"4.0.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Cytopathology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jasc.2019.07.005","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T12:56:50Z","timestamp":1565269010000},"page":"352-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma"],"prefix":"10.1016","volume":"8","author":[{"given":"Momin T.","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Churg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jasc.2019.07.005_bib1","series-title":"Practical Pathology of Serous Membranes","first-page":"1","article-title":"The mesothelium","author":"Krausz","year":"2019"},{"key":"10.1016\/j.jasc.2019.07.005_bib2","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1056\/NEJMvcm053812","article-title":"Videos in clinical medicine: thoracentesis","volume":"355","author":"Thomsen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jasc.2019.07.005_bib3","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","article-title":"Malignant mesothelioma mortality\u2014United States, 1999-2015","volume":"66","author":"Mazurek","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jasc.2019.07.005_bib4","series-title":"Cytology: Diagnostic Principles and Clinical Correlates","author":"Cibas","year":"2014"},{"key":"10.1016\/j.jasc.2019.07.005_bib5","first-page":"320","article-title":"Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination","volume":"4","author":"Nance","year":"1991","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.chest.2016.01.023","article-title":"Risk of procedural hemorrhage","volume":"150","author":"Wolfe","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jasc.2019.07.005_bib7","first-page":"1058","article-title":"Pleural procedural complications: prevention and management","volume":"7","author":"Corcoran","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jasc.2019.07.005_bib8","first-page":"P3073","article-title":"Efficacy of cytology, cell blocks and thoracoscopic pleural biopsy in malignant pleural effusion diagnosis","volume":"42","author":"Altman","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jasc.2019.07.005_bib9","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/1535-7163.MCT-16-0436","article-title":"Cell-free DNA from ascites and pleural effusions: molecular insights into genomic aberrations and disease biology","volume":"16","author":"Husain","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jasc.2019.07.005_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41379-018-0138-z","article-title":"The utilization of cytologic and small biopsy samples for ancillary molecular testing","author":"Roh","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib11","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.21037\/jtd.2017.10.125","article-title":"The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review","volume":"10","author":"Al\u00ec","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jasc.2019.07.005_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cncy.21928","article-title":"A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma","volume":"126","author":"Kinoshita","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib13","series-title":"Molecular Applications in Cytology","author":"Schmitt","year":"2018"},{"key":"10.1016\/j.jasc.2019.07.005_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2019.07.005_bib16","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00018-008-7440-8","article-title":"The epidermal growth factor receptor family: biology driving targeted therapeutics","volume":"65","author":"Wieduwilt","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jasc.2019.07.005_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.drudis.2017.10.004","article-title":"Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors","volume":"23","author":"Singh","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jasc.2019.07.005_bib18","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hanna","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jasc.2019.07.005_bib19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cllc.2016.05.016","article-title":"EGFR testing in advanced non-small-cell lung cancer, a mini-review","volume":"17","author":"Sheikine","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jasc.2019.07.005_bib20","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2147\/OTT.S125397","article-title":"EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?","volume":"10","author":"Joshi","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jasc.2019.07.005_bib21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/jclinpath-2012-201194","article-title":"EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples","volume":"66","author":"Ellison","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib22","author":"Wetterstrand"},{"key":"10.1016\/j.jasc.2019.07.005_bib23","article-title":"Next-generation sequencing technologies","author":"McCombie","year":"2018","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"10.1016\/j.jasc.2019.07.005_bib24","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/gim.2017.247","article-title":"Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature","volume":"20","author":"Schwarze","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.jasc.2019.07.005_bib25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","volume":"36","author":"Kalemkerian","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jasc.2019.07.005_bib26","doi-asserted-by":"crossref","DOI":"10.4238\/gmr.15027001","article-title":"Comparison of EGFR mutation rates in lung adenocarcinoma tissue and pleural effusion samples","volume":"15","author":"Guan","year":"2016","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.jasc.2019.07.005_bib27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncy.21260","article-title":"High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas","volume":"121","author":"Sun","year":"2013","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib28","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4143\/crt.2017.378","article-title":"EGFR mutation status in lung adenocarcinoma-associated malignant pleural effusion and efficacy of EGFR tyrosine kinase inhibitors","volume":"50","author":"Yang","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jasc.2019.07.005_bib29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2013.04.023","article-title":"Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing","volume":"81","author":"Yeo","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jasc.2019.07.005_bib30","first-page":"8813","article-title":"Detection of EGFR mutation in supernatant, cell pellets of pleural effusion and tumor tissues from non-small cell lung cancer patients by high resolution melting analysis and sequencing","volume":"7","author":"Lin","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib31","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1186\/s12885-018-5138-3","article-title":"Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jasc.2019.07.005_bib32","first-page":"929","article-title":"Identification of EGFR mutations in cytological specimens of non-small cell lung carcinoma from a single institute","volume":"11","author":"Wang","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib33","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1093\/annonc\/mds121","article-title":"An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting","volume":"23","author":"Goto","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jasc.2019.07.005_bib34","doi-asserted-by":"crossref","first-page":"e0168625","DOI":"10.1371\/journal.pone.0168625","article-title":"The role of liquid based cytology and ancillary techniques in the peritoneal washing analysis: our institutional experience","volume":"12","author":"Rossi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jasc.2019.07.005_bib35","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/cncy.21518","article-title":"The role of liquid-based cytology and ancillary techniques in pleural and pericardiac effusions: an institutional experience","volume":"123","author":"Rossi","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib36","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1158\/1078-0432.CCR-12-1958","article-title":"Effective assessment of EGFR mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing","volume":"19","author":"Buttitta","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jasc.2019.07.005_bib37","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1080\/15384047.2015.1095407","article-title":"Anaplastic lymphoma kinase: role in cancer and therapy perspective","volume":"16","author":"Zhao","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jasc.2019.07.005_bib38","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.3747\/co.25.3760","article-title":"ALK inhibitors, resistance development, clinical trials","volume":"25","author":"Rothenstein","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jasc.2019.07.005_bib39","first-page":"1169","article-title":"Molecular profiling of malignant pleural effusion in metastatic non\u2013small-cell lung carcinoma: the effect of preanalytical factors","volume":"14","author":"Carter","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jasc.2019.07.005_bib40","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/cncy.21288","article-title":"Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma","volume":"121","author":"Cai","year":"2013","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncy.21510","article-title":"Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization","volume":"123","author":"Wang","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib42","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.humpath.2014.02.015","article-title":"Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients","volume":"45","author":"Wang","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib43","doi-asserted-by":"crossref","first-page":"e0117032","DOI":"10.1371\/journal.pone.0117032","article-title":"Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jasc.2019.07.005_bib44","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.1158\/1078-0432.CCR-11-2947","article-title":"A prospective PCR-based screening for the EML4-ALK oncogene in non\u2013small cell lung cancer","volume":"18","author":"Soda","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jasc.2019.07.005_bib45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/JTO.0b013e3182370e30","article-title":"EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR","volume":"7","author":"Wu","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jasc.2019.07.005_bib46","doi-asserted-by":"crossref","first-page":"e0158125","DOI":"10.1371\/journal.pone.0158125","article-title":"Epidermal growth factor receptor mutation and anaplastic lymphoma kinase gene fusion: detection in malignant pleural effusion by RNA or PNA analysis","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jasc.2019.07.005_bib47","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/JTO.0000000000000203","article-title":"Multiplexed molecular profiling of lung cancer using pleural effusion","volume":"9","author":"Akamatsu","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jasc.2019.07.005_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-019-02559-z","article-title":"Invited review\u2014next-generation sequencing: a modern tool in cytopathology","volume":"475","author":"Roy-Chowdhuri","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jasc.2019.07.005_bib49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.lungcan.2015.02.018","article-title":"Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion","volume":"88","author":"Tsai","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jasc.2019.07.005_bib50","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.21037\/jtd.2018.04.125","article-title":"Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens","volume":"10","author":"Liu","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jasc.2019.07.005_bib51","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jmoldx.2017.10.007","article-title":"Comprehensive genomic profiling of malignant effusions in patients with metastatic lung adenocarcinoma","volume":"20","author":"Yang","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jasc.2019.07.005_bib52","doi-asserted-by":"crossref","first-page":"e23206","DOI":"10.1200\/JCO.2017.35.15_suppl.e23206","article-title":"Lung cancer genomic alterations in cell free DNA in pleural effusion compared to plasma","volume":"35","author":"Zhou","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jasc.2019.07.005_bib53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cell.2019.02.049","article-title":"A tumor-agnostic NTRK (TRK) inhibitor","volume":"177","author":"Huang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jasc.2019.07.005_bib55","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.2017.77.1899","article-title":"Targeting HER2 by combination therapies","volume":"36","author":"Ruiz-Saenz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jasc.2019.07.005_bib56","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1634\/theoncologist.8-4-307","article-title":"The Her-2\/neu gene and protein in breast cancer 2003: biomarker and target of therapy","volume":"8","author":"Ross","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.jasc.2019.07.005_bib57","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.18295\/2075-0528.1651","article-title":"A brief history of breast cancer: part III\u2014tumour biology lays the foundation for medical oncology","volume":"15","author":"Lakhtakia","year":"2015","journal-title":"Sultan Qaboos Univ Med J"},{"key":"10.1016\/j.jasc.2019.07.005_bib58","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/EDBK_201037","article-title":"Evolution of targeted therapy in breast cancer: where precision medicine began","volume":"38","author":"Meisel","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jasc.2019.07.005_bib59","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrclinonc.2016.15","article-title":"Clinical impact of tumour biology in the management of gastroesophageal cancer","volume":"13","author":"Lordick","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jasc.2019.07.005_bib60","first-page":"141","article-title":"Molecular subtypes and personalized therapy in metastatic colorectal cancer","volume":"12","author":"Graham","year":"2016","journal-title":"Curr Colorectal Cancer Rep"},{"key":"10.1016\/j.jasc.2019.07.005_bib61","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2019.07.005_bib62","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10555-016-9631-3","article-title":"Estrogen, progesterone, and HER2\/neu receptor discordance between primary and metastatic breast tumours\u2014a review","volume":"35","author":"Yeung","year":"2016","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jasc.2019.07.005_bib63","doi-asserted-by":"crossref","first-page":"10936","DOI":"10.3748\/wjg.v21.i39.10936","article-title":"Evaluation and treatment of malignant ascites secondary to gastric cancer","volume":"21","author":"Maeda","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jasc.2019.07.005_bib64","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3892\/ol.2015.2843","article-title":"Refractory left pleural effusion in an older patient: atypical presentation of colorectal carcinoma","volume":"9","author":"Yuan","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jasc.2019.07.005_bib65","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/dc.21389","article-title":"Reliability of Her2\/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma","volume":"39","author":"Shabaik","year":"2011","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib66","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00432-010-0790-2","article-title":"Combined detection of Her2\/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer","volume":"136","author":"Schluter","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jasc.2019.07.005_bib67","first-page":"55","article-title":"Discordant HER2 status between primary breast carcinoma and recurrent\/metastatic tumors using fluorescence in situ hybridization on cytological samples","volume":"43","author":"Ogawa","year":"2012","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jasc.2019.07.005_bib68","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12282-015-0615-x","article-title":"Benefits of using the cell block method to determine the discordance of the HR\/HER2 expression in patients with metastatic breast cancer","volume":"23","author":"Nakayama","year":"2016","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jasc.2019.07.005_bib69","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/bjc.2011.121","article-title":"Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma","volume":"104","author":"Bozzetti","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jasc.2019.07.005_bib70","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/dc.23212","article-title":"HER2 testing in malignant effusions of metastatic gastric carcinoma: is it feasible?","volume":"43","author":"Wong","year":"2015","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib71","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-7-152","article-title":"The BRCA1\/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers","volume":"7","author":"Friedenson","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jasc.2019.07.005_bib72","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1758834017714993","article-title":"BRCA mutation in ovarian cancer: testing, implications and treatment considerations","volume":"9","author":"Neff","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jasc.2019.07.005_bib73","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/cancers10120487","article-title":"Role of BRCA mutations in cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors","volume":"10","author":"Faraoni","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jasc.2019.07.005_bib74","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4174\/astr.2017.92.5.331","article-title":"Next-generation sequencing of BRCA1\/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results","volume":"92","author":"Park","year":"2017","journal-title":"Ann Surg Treat Res"},{"key":"10.1016\/j.jasc.2019.07.005_bib75","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12885-019-5535-2","article-title":"Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1\/2 genes in patients with tubo-ovarian high grade serous carcinoma","volume":"19","author":"Gornjec","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jasc.2019.07.005_bib76","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cncy.21342","article-title":"The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey","volume":"121","author":"Paintal","year":"2013","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib77","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.humpath.2012.11.016","article-title":"Broad-spectrum immunohistochemical epithelial markers: a review","volume":"44","author":"Ord\u00f3\u00f1ez","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jasc.2019.07.005_bib78","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New markers for separating benign from malignant mesothelial proliferations: are we there yet?","volume":"140","author":"Churg","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2019.07.005_bib79","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jasc.2019.07.005_bib80","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2019.07.005_bib81","doi-asserted-by":"crossref","first-page":"68863","DOI":"10.18632\/oncotarget.20317","article-title":"Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jasc.2019.07.005_bib82","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/PAS.0000000000000529","article-title":"Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"}],"container-title":["Journal of the American Society of Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294519301061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294519301061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T06:46:09Z","timestamp":1761979569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213294519301061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S2213294519301061"],"URL":"https:\/\/doi.org\/10.1016\/j.jasc.2019.07.005","relation":{},"ISSN":["2213-2945"],"issn-type":[{"value":"2213-2945","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Cytopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jasc.2019.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}